Janus kinase inhibitors: An innovative treatment for alopecia areata

2019 ◽  
Vol 46 (8) ◽  
pp. 724-730 ◽  
Author(s):  
Hyunsun Park ◽  
Da‐Ae Yu ◽  
Ohsang Kwon
Keyword(s):  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors ◽  
Innovative Treatment

The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Ana B. Oliveira ◽  
Miguel Alpalhão ◽  
Paulo Filipe ◽  
João Maia‐Silva
Keyword(s):  
Systematic Review ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals APPLICATION OF JANUS-KINASE INHIBITORS IN THE TREATMENT OF ALOPECIA AREATA (LITERATURE REVIEW)

2019 ◽  
Vol 22 (1-2) ◽  
pp. 61-64
Author(s):  
Anfisa A. Lepekhova ◽  
L. M Chernyavskaya
Keyword(s):  
Literature Review ◽  
Mechanism Of Action ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Targeted Drugs ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated ◽  
Adults And Children

Based on the analysis of data from modern foreign sources current information about using of Janus-kinase inhibitors, in particular, tofacitinid and ruxolitinid, for the treatment of alopecia areata in adults and children, in the presence of a lesion of the scalp and other areas (eyebrows, eyelashes) is shown. The information about the mechanism of action of Janus-kinase inhibitors, the efficacy and safety of their use, possible methods of use, prospects for further research in the treatment of alopecia areata using targeted drugs is presented. The pathogenetic rationale for the possibility of using this group of drugs for treating immune-mediated diseases, for instance, alopecia areata is described.

scholarly journals Role of janus kinase inhibitors in the treatment of alopecia areata

2018 ◽  
Vol Volume 12 ◽  
pp. 2323-2335 ◽  
Author(s):  
Korn Triyangkulsri ◽  
Poonkiat Suchonwanit
Keyword(s):  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

Dermatology ◽  
2018 ◽  
Vol 235 (2) ◽  
pp. 130-136 ◽  
Author(s):  
Nawaf Almutairi ◽  
Tarek M. Nour ◽  
Nasser Haji  Hussain
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Autoimmune Disorder ◽  
Janus Kinase ◽  
Open Label ◽  
Janus Kinase Inhibitors ◽  
Hair Regrowth ◽  
Significant Difference

Background: Alopecia areata (AA) is a common autoimmune disorder characterized by patchy hair loss. There are many treatments available for AA. However, treatments of severe forms of AA are not satisfactory. Recently, oral Janus kinase (JAK) inhibitors were found to be effective for the treatment of severe AA variants. Objective: The aim of this work was to evaluate and compare the efficacy, side effects, and durability of two oral JAK inhibitor medications (ruxolitinib and tofacitinib) in the treatment of severe AA. Methods: This study included 75 patients with AA with more than 30% scalp hair loss, alopecia totalis, and alopecia universalis randomized into 2 groups. The first group (n = 38) received ruxolitinib 20 mg twice daily, and the second group (n = 37) received oral tofacitinib 5 mg twice daily. The treatment continued for 6 months followed by 3 months of follow-up off therapy. Efficacy of treatment was assessed by monitoring the change in the Severity of Alopecia Tool (SALT) score. Results: Both tofacitinib and ruxolitinib induced remarkable hair regrowth, with a mean change in SALT score of 93.8 ± 3.25 in the ruxolitinib group and 95.2 ± 2.69 in the tofacitinib group. However, the ruxolitinib group showed a shorter duration for initial hair regrowth. There was no statistically significant difference between the groups regarding hair regrowth at the end of the 6-month treatment and relapse rate at the end of the 3-month follow-up. Around two thirds of cases experienced relapse. Both drugs were well tolerated, with no reported serious adverse effects. Conclusion: Both ruxolitinib and tofacitinib could be considered effective and well-tolerated treatments for extensive AA.

Sign in / Sign up

Export Citation Format

Share Document